Targeted inhibition of human hematological cancers in vivo by doxorubicin encapsulated in smart lipoic acid-crosslinked hyaluronic acid nanoparticles

References

• Anchordoquy TJ, Barenholz Y, Boraschi D, et al. (2017). Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions. ACS Nano 11:12–18.
   PubMed Web of Science ®Google Scholar
• Babar IA, Cheng CJ, Booth CJ, et al. (2012). Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA 109:E1695–704.
   PubMed Web of Science ®Google Scholar
• Baz R, Walker E, Karam M, et al. (2006). Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17:1766–71.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, et al. (2014). Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 66:2–25.
   PubMed Web of Science ®Google Scholar
• Burnett A, Wetzler M, Löwenberg B. (2011). Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29:487–94.
   PubMed Web of Science ®Google Scholar
• Cadete A, Alonso MJ. (2016). Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives. Nanomedicine (Lond) 11:2341–57.
   PubMed Web of Science ®Google Scholar
• Chapman MA, Lawrence MS, Keats JJ, et al. (2011). Initial genome sequencing and analysis of multiple myeloma. Nature 471:467–72.
   PubMed Web of Science ®Google Scholar
• Chen P, Qiu M, Deng C, et al. (2015). pH-responsive chimaeric pepsomes based on asymmetric poly (ethylene glycol)-b-poly (l-leucine)-b-poly (l-glutamic acid) triblock copolymer for efficient loading and active intracellular delivery of doxorubicin hydrochloride. Biomacromolecules 16:1322–30.
   PubMed Web of Science ®Google Scholar
• Chen C, Zhou B, Zhu X, et al. (2016a). Branched polyethyleneimine modified with hyaluronic acid via a PEG spacer for targeted anticancer drug delivery. RSC Adv 6:9232–9.
   Web of Science ®Google Scholar
• Chen J, Zou Y, Deng C, et al. (2016b). Multifunctional click hyaluronic acid nanogels for targeted protein delivery and effective cancer treatment in vivo. Chem Mater 28:8792–9.
   Web of Science ®Google Scholar
• Cohen K, Emmanuel R, Kisin-Finfer E, et al. (2014). Modulation of drug resistance in ovarian adenocarcinoma using chemotherapy entrapped in hyaluronan-grafted nanoparticle clusters. ACS Nano 8:2183–95.
   PubMed Web of Science ®Google Scholar
• Dosio F, Arpicco S, Stella B, et al. (2016). Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev 97:204–36.
   PubMed Web of Science ®Google Scholar
• Fan D, Wu C, Wang K, et al. (2016). A polydopamine nanosphere based highly sensitive and selective aptamer cytosensor with enzyme amplification. Chem Commun (Camb) 52:406–9.
   PubMed Web of Science ®Google Scholar
• Feldman EJ, Lancet JE, Kolitz JE, et al. (2011). First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5: 1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 29:979–85.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Schiffer CA. (2013). Acute myeloid leukaemia in adults. Lancet 381:484–95.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Iyer AK, Morrissey DV, et al. (2013). Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 34:3489–502.
   PubMed Web of Science ®Google Scholar
• Gao J, Li W, Guo Y, et al. (2016). Nanomedicine strategies for sustained, controlled and targeted treatment of cancer stem cells. Nanomedicine 11:3261–82.
   PubMed Web of Science ®Google Scholar
• Hazan-Halevy I, Landesman-Milo D, Rosenblum D, et al. (2016). Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines. J Control Release 244:149–56.
   PubMed Web of Science ®Google Scholar
• Hu Q, Qian C, Sun W, et al. (2016). Engineered nanoplatelets for enhanced treatment of multiple myeloma and thrombus. Adv Mater 28:9573–80.
   PubMed Web of Science ®Google Scholar
• Jin L, Hope KJ, Zhai Q, et al. (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12:1167–74.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Xu X, Kelly D, et al. (2015). CD19-Targeted nanodelivery of doxorubicin enhances therapeutic efficacy in B-cell acute lymphoblastic leukemia. Mol Pharm 12:2101–11.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Cortes JE, Hogge DE, et al. (2014). Phase 2 trial of CPX-351, a fixed 5: 1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 123:3239–46.
   PubMed Web of Science ®Google Scholar
• Li J, He Y, Sun W, et al. (2014). Hyaluronic acid-modified hydrothermally synthesized iron oxide nanoparticles for targeted tumor MR imaging. Biomaterials 35:3666–77.
   PubMed Web of Science ®Google Scholar
• Li J, Hu Y, Yang J, et al. (2015). Hyaluronic acid-modified Fe3O4@Au core/shell nanostars for multimodal imaging and photothermal therapy of tumors. Biomaterials 38:10–21.
   PubMed Web of Science ®Google Scholar
• Liang J, Jiang D, Noble PW. (2016). Hyaluronan as a therapeutic target in human diseases. Adv Drug Deliv Rev 97:186–203.
   PubMed Web of Science ®Google Scholar
• Liu G, Choi KY, Bhirde A, et al. (2012). Sticky nanoparticles: a platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate. Angew Chem Int Ed 51:445–9.
   PubMed Web of Science ®Google Scholar
• Mahindra A, Laubach J, Raje N, et al. (2012). Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 9:135–43.
   PubMed Web of Science ®Google Scholar
• Misaghian N, Ligresti G, Steelman L, et al. (2009). Targeting the leukemic stem cell: the holy grail of leukemia therapy. Leukemia 23:25–42.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Ludwig H, et al. (2011). Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118:4519–29.
   PubMed Web of Science ®Google Scholar
• Quere R, Andradottir S, Brun A, et al. (2011). High levels of the adhesion molecule CD44 on leukemic cells generate acute myeloid leukemia relapse after withdrawal of the initial transforming event. Leukemia 25:515–26.
   PubMed Web of Science ®Google Scholar
• Rao NV, Yoon HY, Han HS, et al. (2016). Recent developments in hyaluronic acid-based nanomedicine for targeted cancer treatment. Expert Opin Drug Deliv 13:239–52.
   PubMed Web of Science ®Google Scholar
• Shah NN, Merchant MS, Cole DE, et al. (2016). Vincristine sulfate liposomes injection (VSLI, Marqibo®): results from a phase I study in children, adolescents, and young adults with refractory solid tumors or leukemias. Pediatr Blood Cancer 63:997–1005.
   PubMed Web of Science ®Google Scholar
• Shen S, Xia J-X, Wang J. (2016). Nanomedicine-mediated cancer stem cell therapy. Biomaterials 74:1–18.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2016). Cancer statistics, 2016. CA Cancer J Clin 66:7–30.
   PubMed Web of Science ®Google Scholar
• Sun D, Zhou J-K, Zhao L, et al. (2017). Novel curcumin liposome modified with hyaluronan targeting CD44 plays an anti-leukemic role in acute myeloid leukemia in vitro and in vivo. ACS Appl Mater Interfaces 9:16857–68.
   PubMed Web of Science ®Google Scholar
• Swami A, Reagan MR, Basto P, et al. (2014). Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci USA 111:10287–92.
   PubMed Web of Science ®Google Scholar
• Tatar A-S, Nagy-Simon T, Tomuleasa C, et al. (2016). Nanomedicine approaches in acute lymphoblastic leukemia. J Control Release 238:123–38.
   PubMed Web of Science ®Google Scholar
• Toole BP. (2004). Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4:528–39.
   PubMed Web of Science ®Google Scholar
• Van Der Meel R, Lammers T, Hennink WE. (2017). Cancer nanomedicines: oversold or underappreciated? Expert Opin Drug Deliv 14:1–5.
   PubMed Web of Science ®Google Scholar
• Visani G, Loscocco F, Isidori A. (2014). Nanomedicine strategies for hematological malignancies: what is next? Nanomedicine 9:2415–28.
   PubMed Web of Science ®Google Scholar
• Wang H, Agarwal P, Zhao S, et al. (2015). Hyaluronic acid-decorated dual responsive nanoparticles of Pluronic F127, PLGA, and chitosan for targeted co-delivery of doxorubicin and irinotecan to eliminate cancer stem-like cells. Biomaterials 72:74–89.
   PubMed Web of Science ®Google Scholar
• Wang L, Jia E. (2016). Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance. Drug Deliv 23:1810–17.
   PubMed Web of Science ®Google Scholar
• Weinstein S, Toker IA, Emmanuel R, et al. (2016). Harnessing RNAi-based nanomedicines for therapeutic gene silencing in B-cell malignancies. Proc Natl Acad Sci USA 113:E16–22.
   PubMed Web of Science ®Google Scholar
• Wu L, Zou Y, Deng C, et al. (2013). Intracellular release of doxorubicin from core-crosslinked polypeptide micelles triggered by both pH and reduction conditions. Biomaterials 34:5262–72.
   PubMed Web of Science ®Google Scholar
• Yan H, Song J, Jia X, et al. (2017). Hyaluronic acid-modified didecyldimethylammonium bromide/ d-a-tocopheryl polyethylene glycol succinate mixed micelles for delivery of baohuoside I against non-small cell lung cancer: in vitro and in vivo evaluation. Drug Deliv 24:30–9.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Goltsche K, Cheng L, et al. (2016). Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo. Biomaterials 84:250–61.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Zhang J, Cheng R, et al. (2015). Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. J Control Release 205:144–54.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Xie Q. (2016). Hyaluronic acid-coated magnetic nanoparticles-based selective collection and detection of leukemia cells with quartz crystal microbalance. Sens Actuators B Chem 223:9–14.
   Web of Science ®Google Scholar
• Zhu Y, Zhang J, Meng F, et al. (2016). cRGD-functionalized reduction-sensitive shell-sheddable biodegradable micelles mediate enhanced doxorubicin delivery to human glioma xenografts in vivo. J Control Release 233:29–38.
   PubMed Web of Science ®Google Scholar
• Zöller M. (2011). CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 11:254–67.
   PubMed Web of Science ®Google Scholar